Form 4: Maxcyte CFO Acquires Stock Options
Statement of Changes in Beneficial Ownership
Maxcyte, Inc. reports that Chief Financial Officer Parmeet Ahuja acquired 375,000 employee stock options.
Summary
- Parmeet Ahuja, Chief Financial Officer of Maxcyte, Inc., acquired 375,000 employee stock options on March 30, 2026.
- The options have an exercise price of $0.6762 and an expiration date of March 29, 2036.
- Vesting begins with 25% on March 30, 2027, followed by 36 equal monthly installments, contingent on continued service.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents a standard executive compensation practice rather than a significant financial event or strategic shift.
Positives
- The acquisition of stock options by the CFO can signal confidence in the company's future prospects.
- The vesting schedule encourages long-term commitment from the executive.
Risks
- The value of the stock options is directly tied to the future performance of Maxcyte, Inc.'s stock price.
- Continued service is a condition for vesting, meaning the CFO could forfeit unvested options if employment ceases.
Future Outlook
The vesting schedule indicates a forward-looking commitment tied to continued service and company performance over the next several years.
Industry Context
StockSavvy.ai notes that the granting of stock options to key executives is a common practice in the biotechnology and life sciences sector to align executive interests with shareholder value and incentivize long-term growth.
Stakeholder Impact
- Shareholders: The grant of options does not immediately impact share count but represents potential future dilution if exercised. It can also be seen as a positive signal of executive commitment.
- Employees: May be part of a broader compensation strategy that affects morale and retention.
- Management: Reinforces the alignment of executive compensation with company performance.
Next Steps
- Continued service by Parmeet Ahuja through the vesting dates.
- Potential exercise of stock options upon vesting, subject to market conditions and personal financial planning.
Key Dates
| Date | Description |
|---|---|
| 03/30/2026 | Earliest transaction date and acquisition date of stock options. |
| 03/29/2036 | Expiration date of the acquired stock options. |
| 03/30/2027 | First vesting date for 25% of the stock options. |
| 04/10/2026 | Date of signature for the filing. |
Keywords
Maxcyte Inc, MXCT, Form 4, Stock Options, Executive Compensation, Beneficial Ownership, Insider Trading, Securities Exchange Act
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.